Please login to the form below

Not currently logged in
Email:
Password:

SHP465

This page shows the latest SHP465 news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

Formerly known as SHP465, Mydayis has been approved to treat ADHD in children aged over 13 and adults, as in younger patients it has higher rates of adverse reaction such as

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    While Intuniv remains an important ADHD product for Shire, the company's main near-term ambition in the category is securing approval for SHP465, a mixed amphetamine salt product that it

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the ... SHP465 will provide 16 hours cover from a single tablet, extending from the morning

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics